Education
About Us
Working with TipRanks
Follow Us
Xeris Pharmaceuticals (XERS)
NASDAQ:XERS
Top Page
Xeris Pharmaceuticals
(NASDAQ:XERS)
Select Model
Select Model
Rating:46Neutral
Price Target:
$7.00
▼(-9.21% Downside)
Xeris Pharmaceuticals faces significant financial challenges, with high leverage and negative equity being major concerns. Despite strong revenue growth and positive developments like the XP-8121 patent allowance, the stock's valuation and technical indicators are weak. The earnings call provided some optimism with record revenue growth and positive cash flow, but increased expenses and competition remain risks.
Positive Factors
Revenue Growth
Strong revenue growth indicates expanding market reach and product adoption, providing a solid foundation for future profitability.
Patent Allowance
Securing the XP-8121 patent strengthens Xeris' intellectual property, enhancing competitive positioning and potential market share.
Cash Flow Improvement
Positive cash flow and net income indicate improved financial health, enabling reinvestment in growth and innovation.
Negative Factors
High Leverage
High leverage can strain financial flexibility, increasing vulnerability to economic downturns and limiting strategic options.
Profitability Challenges
Ongoing profitability issues suggest operational inefficiencies, which could hinder long-term growth and investor confidence.
Increased Expenses
Rising expenses, particularly in R&D, may pressure margins and require careful management to ensure sustainable growth.
Xeris Pharmaceuticals (XERS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.31B
Dividend YieldN/A
Average Volume (3M)2.26M
Price to Earnings (P/E)―
Beta (1Y)1.30
Revenue Growth42.05%
EPS Growth76.50%
CountryUS
Employees394
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.00
Shares Outstanding165,924,290
10 Day Avg. Volume2,786,077
30 Day Avg. Volume2,262,980
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)-16.80
Price to Sales (P/S)2.45
P/FCF Ratio-13.15
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$11.00Price Target Upside42.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.18
Revenue Forecast (FY)$367.52M
Xeris Pharmaceuticals Business Overview & Revenue Model
Company DescriptionXeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
How the Company Makes MoneyXeris Pharmaceuticals generates revenue primarily through the commercialization of its proprietary products, such as XeriJect and other formulations in its pipeline. The company's revenue model includes sales of these products to healthcare providers and patients, as well as potential licensing agreements with larger pharmaceutical companies. Additionally, Xeris may benefit from partnerships that provide upfront payments, milestone payments, and royalties based on sales of partnered products. The company’s focus on innovative delivery systems positions it to capture market share in the growing injectable drug market, thereby contributing to its overall earnings.
Xeris Pharmaceuticals Earnings Call Summary
Earnings Call Date:Nov 06, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Mar 11, 2026
Earnings Call Sentiment Positive
The earnings call highlighted Xeris Biopharma's strong financial performance with record revenue growth and successful product performance, particularly for RECORLEV. However, there are increased expenses and potential competitive challenges on the horizon. Despite these concerns, the company's positive financial milestones and strategic growth plans suggest an optimistic outlook.Q3-2025 Updates
Positive Updates
Record-Breaking Revenue Growth
Total product revenue exceeded $74 million, representing a 40% increase year-over-year. The full year total revenue guidance was raised to be in the range of $285 million to $290 million, a 42% increase at the midpoint.
RECORLEV Performance
RECORLEV remained the primary growth engine with revenue of $37 million in the quarter, a year-over-year increase of 109%. The average number of patients on therapy grew by 108% versus the same period last year.
Gvoke and KEVEYIS Performance
Gvoke delivered a solid quarter with revenue of more than $25 million, up nearly 10% from the same period last year. KEVEYIS revenue was approximately $12 million, driven by growth in the average number of patients on therapy.
Financial Milestones
The company generated significant positive cash flow and net income for the first time in its history. Adjusted EBITDA for the quarter was $17.4 million, improving more than $20 million compared to Q3 2024.
Negative Updates
Increased Expenses
R&D expenses increased by $1.6 million compared to the previous year, primarily due to continued investment in the pipeline and technology platforms. SG&A expenses also rose by approximately 3% due to incremental personnel-related expenses.
Potential Impact of Competition
There is anticipation of new competition from Corcept's relacorilant, which could impact RECORLEV, though the company remains optimistic about overall market growth.
Company Guidance
During the Xeris Biopharma Q3 2025 earnings call, the company provided robust guidance, highlighting a record-setting quarter with total product revenue exceeding $74 million, marking a 40% year-over-year increase. The company raised the lower end of its full-year total revenue guidance to between $285 million and $290 million, reflecting a 42% increase at the midpoint compared to 2024. Key metrics driving this growth included a 109% increase in RECORLEV revenue, reaching $37 million, and a 108% rise in the average number of patients on RECORLEV therapy. Gvoke's revenue was over $25 million, up nearly 10% year-over-year, while KEVEYIS generated approximately $12 million, driven by new patient additions. Additionally, the company reported improving gross margins at 85%, significant positive cash flow, and net income for the first time. Looking forward, Xeris plans strategic investments in its RECORLEV commercial organization and the development of XP-8121, aiming to maintain positive adjusted EBITDA amidst a continued focus on scalable growth.Xeris Pharmaceuticals Financial Statement Overview
Summary
Xeris Pharmaceuticals is experiencing revenue growth but faces significant challenges in profitability and financial stability. The high leverage and negative equity position pose risks, while cash flow management remains a critical area for improvement.Income Statement
Xeris Pharmaceuticals shows a positive revenue growth rate of 8.18% in the TTM, indicating a growing top line. However, the company is struggling with profitability, as evidenced by a negative net profit margin of -13.01% and a negative EBIT margin. The gross profit margin remains strong at 81.14%, but the company needs to address its operational inefficiencies to improve overall profitability.Balance Sheet
The balance sheet reveals significant financial leverage with a high debt-to-equity ratio of -13.32 in the TTM, indicating potential financial risk. The negative stockholders' equity suggests that liabilities exceed assets, which is concerning. Return on equity is positive at 1.14%, but this is due to negative equity, which distorts the metric.Cash Flow
The cash flow statement shows a concerning decline in free cash flow growth of -398.69% in the TTM, highlighting cash management challenges. However, the free cash flow to net income ratio is positive at 1.05, indicating that the company is generating cash relative to its net losses. The operating cash flow to net income ratio is negative, reflecting ongoing operational cash flow issues.| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2023 | Dec 2023 | Dec 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 266.14M | 203.07M | 163.91M | 163.91M | 163.91M | 163.91M |
| Gross Profit | 222.33M | 166.24M | 135.27M | 135.27M | 135.27M | 135.27M |
| EBITDA | 26.62M | -13.99M | -23.73M | -23.73M | -23.73M | -23.73M |
| Net Income | -15.64M | -54.84M | -62.26M | -62.26M | -62.26M | -62.26M |
Balance Sheet | ||||||
| Total Assets | 370.19M | 323.06M | 322.60M | 322.60M | 322.60M | 322.60M |
| Cash, Cash Equivalents and Short-Term Investments | 91.60M | 71.62M | 72.45M | 72.45M | 72.45M | 72.45M |
| Total Debt | 38.19M | 271.45M | 229.19M | 229.19M | 229.19M | 229.19M |
| Total Liabilities | 371.05M | 352.68M | 329.38M | 329.38M | 329.38M | 329.38M |
| Stockholders Equity | -861.00K | -29.61M | -6.78M | -6.78M | -6.78M | -6.78M |
Cash Flow | ||||||
| Free Cash Flow | 19.82M | -37.85M | -49.29M | -49.29M | -49.29M | -49.29M |
| Operating Cash Flow | 10.56M | -36.98M | -47.02M | -47.02M | -47.02M | -47.02M |
| Investing Cash Flow | 9.65M | 4.88M | -6.00M | -6.00M | -6.00M | -6.00M |
| Financing Cash Flow | 12.05M | 36.17M | -1.61M | -1.61M | -1.61M | -1.61M |
Xeris Pharmaceuticals Technical Analysis
Positive
7.71
Price Trends
7.42
Positive
7.83
Negative
6.42
Positive
Market Momentum
0.12
Negative
54.78
Neutral
62.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XERS, the sentiment is Positive. The current price of 7.71 is above the 20-day moving average (MA) of 7.37, above the 50-day MA of 7.42, and above the 200-day MA of 6.42, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 54.78 is Neutral, neither overbought nor oversold. The STOCH value of 62.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XERS.
Xeris Pharmaceuticals Risk Analysis
Xeris Pharmaceuticals disclosed 83 risk factors in its most recent earnings report. Xeris Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Xeris Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $1.68B | 46.34 | 15.02% | ― | 1128.17% | ― | |
56 Neutral | $1.29B | -10.06 | -23.41% | ― | ― | -37.07% | |
55 Neutral | $1.80B | -5.66 | -129.32% | ― | 597.19% | 0.45% | |
55 Neutral | $2.64B | -6.63 | -68.13% | ― | -8.75% | -8.79% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.75B | -28.24 | -18.46% | ― | 116.21% | 43.93% | |
46 Neutral | $1.31B | -74.56 | ― | ― | 42.05% | 76.50% |
* Healthcare Sector Average
XERS
Xeris Pharmaceuticals
7.71
4.47
137.96%
SNDX
Syndax Pharmaceuticals
20.47
7.67
59.92%
ZYME
Zymeworks
23.92
9.88
70.37%
RCUS
Arcus Biosciences
22.74
8.48
59.47%
STOK
Stoke Therapeutics
30.58
21.09
222.23%
RAPP
Rapport Therapeutics, Inc.
27.10
13.76
103.15%
Xeris Pharmaceuticals Corporate Events
Business Operations and StrategyProduct-Related Announcements
Xeris Pharmaceuticals Secures Patent Allowance for XP-8121
Positive
Dec 1, 2025
On December 1, 2025, Xeris Biopharma Holdings announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for its XP-8121 patent application, marking a significant milestone in the company’s intellectual property strategy. The XP-8121 is a novel formulation designed to address unmet medical needs in hypothyroidism, potentially enhancing Xeris’ market positioning and offering stakeholders promising advancements in drug formulation technology.
The most recent analyst rating on (XERS) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Xeris Pharmaceuticals stock, see the XERS Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.